Correspondingly, treatment with Gal-9 significantly and dose-dependently reduced the viability of AML cells (Fig. 1D, F and Supplementary Fig. 1F–J), with EC50s ranging from 115 to 300 nM (Supplementary Fig. 1K). The gene discussed is LGALS9; the disease is acute myeloid leukemia.